Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Chief Financial Officer | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
X4 Pharmaceuticals, Inc
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 155,983 |
Reported balance
After 2026-10-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 11,767 · Balance 155,983 F1: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.82 to $2.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Of the shares of common stock reported, 64,418 shares represent restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.82 to $2.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Of the shares of common stock reported, 64,418 shares represent restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CTI BIOPHARMA CORP
Report date June 26, 2023 · Filed June 26, 2023
Section 16 reporting ended · disclosed 2023-06-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 1
1 source rowRow 1 · 2023-06-26 · Other · Disposed 17,547 · Balance 0 F1: Includes 420 shares of common stock of the Issuer ("Company Common Stock") purchased by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan prior to the date of this Form 4. F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of Company Common Stock and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.25 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-26 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.19 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-26 · Disposition to issuer · Disposed 315,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-26 · Disposition to issuer · Disposed 83,396 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-06-26 · Disposition to issuer · Disposed 270,216 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-06-26 · Disposition to issuer · Disposed 340,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-06-26 · Disposition to issuer · Disposed 150,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.49 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-06-26 · Disposition to issuer · Disposed 280,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.55 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-06-26 · Disposition to issuer · Disposed 200,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 420 shares of common stock of the Issuer ("Company Common Stock") purchased by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan prior to the date of this Form 4.
F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of Company Common Stock and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:03 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 11,767 | $2.86 | $33,658.33 |
DisclosureSEC source: 0001501697-26-000078 · wk-form4_1791230611.xml · nonDerivative · entry 1 KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,983 F1 · kind: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.82 to $2.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Of the shares of common stock reported, 64,418 shares represent restricted stock units. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:23 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 8,543 | $4.26 | $36,428.21 |
DisclosureSEC source: 0001501697-26-000065 · wk-form4_1782937402.xml · nonDerivative · entry 1 KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,750 F1 · kind: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.21 to $4.31, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Of the shares of common stock reported, 96,627 shares represent restricted stock units. Read SEC document |
| May 12, 2026 Filed May 13, 2026 20:02 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 16,961 | $4.29 | $72,820.36 |
DisclosureSEC source: 0001501697-26-000049 · wk-form4_1778702561.xml · nonDerivative · entry 1 KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,293 F1 · kind: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.20 to $4.45, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Of the shares of common stock reported, 128,836 shares represent restricted stock units. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:41 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 1,552,769 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001276750-25-000004 · wk-form4_1761943312.xml · derivative · entry 1 KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,552,769 Underlying: Common Stock · 1,552,769 shares Expires 2035-08-12 F1 · derivative.exercise_date: Represents stock options granted to the Reporting Person on August 12, 2025, which were subject to a performance-based vesting condition that was satisfied on October 29, 2025. One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 00:31 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 352,800 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001628280-25-040440 · wk-form4_1755217870.xml · derivative · entry 3 KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,800 Underlying: Common Stock · 352,800 shares Expires 2035-08-14 F2 · derivative.exercise_date: One half of the shares subject to the option shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive month thereafter for a period of 12 months, subject to the Reporting Person continuing to provide services through each such date; provided that one half of the shares subject to the option shall vest immediately upon achievement of certain performance-based milestones prior to February 12, 2026. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 00:31 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 193,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-040440 · wk-form4_1755217870.xml · nonDerivative · entry 1 KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,254 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person. One third of the RSUs shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive quarter thereafter for a period of 12 months, subject to the Reporting Person continuing to provide services through each such date and contingent upon approval of the grant at the Issuer's 2026 Annual Meeting of Stockholders. Read SEC document |
| August 12, 2025 Filed Aug 15, 2025 00:31 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 1,073,249 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001628280-25-040440 · wk-form4_1755217870.xml · derivative · entry 2 KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,073,249 Underlying: Common Stock · 1,073,249 shares Expires 2035-08-12 F2 · derivative.exercise_date: One half of the shares subject to the option shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive month thereafter for a period of 12 months, subject to the Reporting Person continuing to provide services through each such date; provided that one half of the shares subject to the option shall vest immediately upon achievement of certain performance-based milestones prior to February 12, 2026. Read SEC document |
| June 26, 2023 Filed Jun 26, 2023 16:05 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Disposition to issuerStock Option (Right to Buy) · Derivative | 200,000 | Not disclosed Strike: $4.55 | Not disclosed |
DisclosureSEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 9 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document |
| June 26, 2023 Filed Jun 26, 2023 16:05 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Disposition to issuerStock Option (Right to Buy) · Derivative | 280,000 | Not disclosed Strike: $4.49 | Not disclosed |
DisclosureSEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 8 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 280,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document |
| June 26, 2023 Filed Jun 26, 2023 16:05 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Disposition to issuerStock Option (Right to Buy) · Derivative | 150,000 | Not disclosed Strike: $3.30 | Not disclosed |
DisclosureSEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 7 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document |
| June 26, 2023 Filed Jun 26, 2023 16:05 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Disposition to issuerStock Option (Right to Buy) · Derivative | 340,000 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 6 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 340,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document |
| June 26, 2023 Filed Jun 26, 2023 16:05 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Disposition to issuerStock Option (Right to Buy) · Derivative | 270,216 | Not disclosed Strike: $0.95 | Not disclosed |
DisclosureSEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 5 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 270,216 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document |
| June 26, 2023 Filed Jun 26, 2023 16:05 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Disposition to issuerStock Option (Right to Buy) · Derivative | 83,396 | Not disclosed Strike: $4.14 | Not disclosed |
DisclosureSEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 4 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,396 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document |
| June 26, 2023 Filed Jun 26, 2023 16:05 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Disposition to issuerStock Option (Right to Buy) · Derivative | 315,000 | Not disclosed Strike: $3.19 | Not disclosed |
DisclosureSEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 3 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 315,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document |
| June 26, 2023 Filed Jun 26, 2023 16:05 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $3.25 | Not disclosed |
DisclosureSEC source: 0000899243-23-016485 · doc4.xml · derivative · entry 2 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document |
| June 26, 2023 Filed Jun 26, 2023 16:05 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | OtherCommon Stock | 17,547 | $9.10 | $159,677.70 |
DisclosureSEC source: 0000899243-23-016485 · doc4.xml · nonDerivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 420 shares of common stock of the Issuer ("Company Common Stock") purchased by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan prior to the date of this Form 4. F2 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of Company Common Stock and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 17:52 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0000899243-23-008752 · doc4.xml · derivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-03-14 F1 · derivative.exercise_date: The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 27,021 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · derivative · entry 16 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,216 Underlying: Common Stock · 27,021 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 27,021 | $6.01 | $162,423.23 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 11 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,127 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 27,021 | $0.95 | $25,640.23 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 10 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,047 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · derivative · entry 15 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,237 Underlying: Common Stock · 1,047 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 800 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · derivative · entry 14 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,284 Underlying: Common Stock · 800 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · derivative · entry 13 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,084 Underlying: Common Stock · 12,000 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 1,047 | $6.01 | $6,292.47 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 9 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,127 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 1,047 | $0.95 | $993.50 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 8 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 800 | $6.01 | $4,804.00 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 7 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,127 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 800 | $0.95 | $759.12 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 6 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 12,000 | $6.00 | $72,000.00 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 5 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,127 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 12,000 | $0.95 | $11,386.80 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 4 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Grantcommon stock | 214 | $5.11 | $1,093.22 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 3 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,127 F2 · kind: Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 13,174 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · derivative · entry 12 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,084 Underlying: Common Stock · 13,174 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 13,174 | $6.00 | $79,044.00 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 2 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,913 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 18:36 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 13,174 | $0.95 | $12,500.81 |
DisclosureSEC source: 0000891293-23-000001 · primary_doc.xml · nonDerivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 16:20 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 609 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-22-000047 · primary_doc.xml · derivative · entry 9 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,258 Underlying: Common Stock · 609 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 16:20 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-22-000047 · primary_doc.xml · derivative · entry 8 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,867 Underlying: Common Stock · 100 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 16:20 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,400 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-22-000047 · primary_doc.xml · derivative · entry 7 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,967 Underlying: Common Stock · 1,400 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 16:20 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 609 | $6.27 | $3,818.43 |
DisclosureSEC source: 0000891293-22-000047 · primary_doc.xml · nonDerivative · entry 6 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,913 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 16:20 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 609 | $0.95 | $577.88 |
DisclosureSEC source: 0000891293-22-000047 · primary_doc.xml · nonDerivative · entry 5 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 16:20 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 100 | $6.26 | $626.00 |
DisclosureSEC source: 0000891293-22-000047 · primary_doc.xml · nonDerivative · entry 4 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,913 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 16:20 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 100 | $0.95 | $94.89 |
DisclosureSEC source: 0000891293-22-000047 · primary_doc.xml · nonDerivative · entry 3 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 16:20 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 1,400 | $6.25 | $8,750.00 |
DisclosureSEC source: 0000891293-22-000047 · primary_doc.xml · nonDerivative · entry 2 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,913 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 16:20 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 1,400 | $0.95 | $1,328.46 |
DisclosureSEC source: 0000891293-22-000047 · primary_doc.xml · nonDerivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 18:26 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 300 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-22-000046 · primary_doc.xml · derivative · entry 12 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,367 Underlying: Common Stock · 300 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 18:26 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 300 | $6.25 | $1,875.00 |
DisclosureSEC source: 0000891293-22-000046 · primary_doc.xml · nonDerivative · entry 8 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,913 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 18:26 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 300 | $0.95 | $284.67 |
DisclosureSEC source: 0000891293-22-000046 · primary_doc.xml · nonDerivative · entry 7 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 18:26 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 139,841 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-22-000046 · primary_doc.xml · derivative · entry 11 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,667 Underlying: Common Stock · 139,841 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 18:26 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 139,841 | $6.05 | $845,548.61 |
DisclosureSEC source: 0000891293-22-000046 · primary_doc.xml · nonDerivative · entry 6 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,913 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 18:26 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 139,841 | $0.95 | $132,695.12 |
DisclosureSEC source: 0000891293-22-000046 · primary_doc.xml · nonDerivative · entry 5 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 18:26 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-22-000046 · primary_doc.xml · derivative · entry 10 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,508 Underlying: Common Stock · 100 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 18:26 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 800 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-22-000046 · primary_doc.xml · derivative · entry 9 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,608 Underlying: Common Stock · 800 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.